CMV Retinitis

This is a serious eye infection caused by the Cytomegalovirus (CMV) virus. It affects the retina, the part of the eye that helps you see. It can lead to vision loss or blindness, especially in people with weakened immune systems like those with AIDS.

Condition

What people with CMV Retinitis report

Every report comes from a Lived member, sent anonymously.

Have you tried Valganciclovir for CMV Retinitis?

NameHow it went

About CMV Retinitis

What It Is

CMV retinitis is an infection of the retina, the light-sensing layer at the back of the eye, caused by cytomegalovirus (CMV). As the virus spreads, it kills patches of retinal tissue, and the vision lost in those areas does not come back. Without treatment, it can lead to blindness within a few months. Some people notice nothing at first, especially when the infection starts at the outer edge of the retina. Others see new floaters (specks or threads drifting across their vision), blind spots or blurring. It usually begins in one eye and often spreads to the other. CMV itself is very common. Between half and four out of five US adults have been infected by age 40, usually without becoming ill, and the virus then stays dormant in the body for life. Retinitis develops when the immune system becomes too weak to keep that dormant virus in check, so it is a sign of severe immune suppression as much as an eye disease.

Causes & Risk Factors

The cause is reactivation of CMV a person already carries, made possible by a deep loss of the immune cells (T cells) that normally control it. Carrying CMV is not a risk in itself for someone with a healthy immune system. What matters is how weak the immune system is and for how long. The best-known setting is advanced HIV infection. Risk is highest when the CD4 count, a blood test that measures the immune cells HIV destroys, falls below 50 cells per microliter. It mostly affects people diagnosed with HIV late, people who have stopped HIV treatment and people whose treatment is not controlling the virus. Effective HIV medicines have made CMV retinitis much less common than it once was. It also occurs outside HIV: after stem cell (bone marrow) or organ transplants, during chemotherapy or treatment with strong immune-suppressing medicines, with prolonged steroid treatment, and in children born with certain immune disorders. In these groups, a recent period of high CMV levels in the blood raises the chance of eye involvement, even after the blood test has turned negative.

How It's Diagnosed

CMV retinitis is diagnosed by looking at the retina. An eye specialist widens (dilates) the pupils with drops and examines the whole retina, including the far edges where early patches often start. Active infection has a recognizable look: areas of white, dying retina, often with bleeding along the blood vessels. Wide-angle photographs record the border of each patch so later exams can show whether it is still growing. Blood tests for CMV cannot confirm or rule out retinitis. The blood test can be negative while the eye is infected, and positive in someone whose eyes are healthy. When the appearance is unusual, or another infection that can look similar is possible (such as other herpes-family viruses or toxoplasmosis), the specialist may draw a tiny sample of fluid from inside the eye and test it for the virus's genetic material, a test called PCR. Because early retinitis can be silent, screening matters. US guidance recommends a dilated eye exam for people with HIV whose CD4 count is below 100, and repeat exams every three to four months while it stays below 50. There is no fixed schedule for transplant or cancer patients; an exam is considered when CMV is active in the blood, immune suppression is intense or vision changes.

Treatment Options

Treatment uses antiviral medicines that stop CMV from copying itself. They halt the spread of retinitis but cannot repair retina that has already been destroyed, which is why starting quickly matters. Treatment begins with an intensive phase (induction) to bring the infection under control, followed by lower-dose maintenance to keep it from returning while immunity is weak. The usual backbone is valganciclovir (Valcyte), an antiviral taken by mouth, or ganciclovir, a closely related drug given by vein. In a trial in people with AIDS, the pill controlled retinitis about as well as the IV drug during the first weeks. Because these medicines travel through the whole body, they also protect the other eye and other organs CMV can attack. When a patch lies close to the center of vision or the optic nerve, a retina specialist also injects antiviral medicine directly into the eye, often weekly at first, to reach high levels where damage would cost the most sight. These medicines have real trade-offs. Ganciclovir and valganciclovir can lower white blood cell, red blood cell and platelet counts, and their doses depend on kidney function, so regular blood tests are part of treatment. They may also affect fertility and could harm a developing pregnancy, which is worth raising before treatment starts. Foscarnet, another IV antiviral, is used when blood counts are too low for ganciclovir or the virus has become resistant to it; it is harder on the kidneys and needs close monitoring of blood minerals. Restoring the immune system is as important as the antiviral. For people with HIV, effective HIV treatment makes the retinitis far less likely to return and is what eventually allows maintenance treatment to stop. For transplant and cancer patients, the care teams weigh whether immune-suppressing treatment can safely be reduced.

What to Expect

With treatment, active retinitis usually stops spreading; across many studies it settled in about nine of ten people. Vision already lost usually stays lost, and measured sharpness of vision improved in only about one in five. Because damage often starts at the edges, a person can keep good central vision while losing parts of their side vision, which matters for activities like moving through crowds or driving. Follow-up is frequent at first. People with HIV are typically re-examined about two weeks after diagnosis and then monthly, with photographs compared each time. For people with HIV, maintenance treatment can usually stop once the retinitis has been inactive, anti-CMV treatment has lasted at least three months and the CD4 count has stayed at 100 or above for at least three months on HIV treatment. It is restarted if the CD4 count falls below 100 again. Outside HIV there is no comparable cutoff, and treatment length follows the course of the underlying immune suppression, sometimes resuming when chemotherapy or transplant medicines are stepped up. Eye problems can continue after the virus is controlled. Healed areas leave thin, scarred retina that can tear and detach, sometimes long after the infection has settled. As immunity returns, some people develop immune recovery uveitis, an inflammation inside the eye that can cause swelling at the center of the retina and blurry vision even though the infection is inactive; it is treated differently from a CMV flare. For these reasons, eye checks continue after antiviral treatment stops, at least every three months at first and about once a year once immunity has been stable. Vision rehabilitation can help people adapt to permanent vision loss.

When to Seek Help

If you have HIV with a CD4 count below 100, or are severely immune-suppressed after a transplant or during cancer treatment and have had CMV in your blood, ask whether you need a dilated eye exam, and keep scheduled eye checks even when your vision seems normal. If you are at risk or have been treated for CMV retinitis, contact your eye or HIV care team right away to arrange an eye exam if you notice blind spots, blurring, new floaters or any other change in vision. Eye pain, redness or worsening vision after an injection into the eye also needs a prompt call to the specialist who gave it. A sudden shower of new floaters, flashes of light, or a curtain or shadow spreading across your vision can mean the retina is detaching. See an eye doctor or go to an emergency department the same day, since prompt repair can protect remaining vision.

Questions to Ask Your Doctor

  1. 1.How close is the infection to the center of my vision or the optic nerve, and does that change how it should be treated?
  2. 2.Is my other eye affected, and how often will both eyes be checked?
  3. 3.Which blood tests will I need while taking these antivirals, and what results would lead you to change the medicine?
  4. 4.What needs to happen with my immune system before maintenance treatment can stop, and what would make it restart?
  5. 5.Do I have permanent vision loss, and would vision rehabilitation or a low-vision assessment help me?

Last reviewed • Oct 2026

Educational content, not medical advice.